Answers are grounded in this paper and cite their sources.
Retrospective analysis shows SGLT2i reduces pseudarthrosis risk in T2DM after hindfoot surgery, indicating potential benefits.
Category: Hindfoot, Other Keywords: Hindfoot Fusion, Hindfoot Arthrodesis, Obesity Introduction/Purpose: Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have gained widespread use in patients with type 2 diabetes mellitus (T2DM) due to their cardiometabolic benefits, and their popularity continues to grow. Recent evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve orthopaedic outcomes, including postoperative recovery, however, whether SGLT2i exert a similar effect on bone healing and surgical outcomes is unknown. Hindfoot arthrodesis procedures, including ankle, triple, and subtalar arthrodesis carry substantial risks of pseudarthrosis and infection. This study aimed to evaluate the association between SGLT2i use and clinical outcomes following hindfoot arthrodesis in patients with T2DM. Methods: We performed a retrospective analysis using the TriNetX US Collaborative Network, which aggregates electronic health records from 71 health care organizations. Patients with T2DM undergoing ankle, triple, or subtalar arthrodesis between 2005–2025 were identified. Two cohorts were created: patients prescribed SGLT2i within one year prior to surgery (n=561) and those without SGLT2i exposure (n=9,012). Outcomes included pseudarthrosis (ICD-10 M96.0) and postsurgical infection (ICD-10 T81.4) within 12 months postoperatively. Propensity score matching was applied for age, sex, race, comorbidities, hemoglobin A1c, body mass index (BMI), and renal function, resulting in 556 patients per group. Risk ratios, odds ratios, and Kaplan–Meier survival analyses were performed, with significance set at p<0.05. This study design ensured balance across metabolic and demographic factors known to influence bone healing and infection risk. Results: Following matching, baseline demographics, HbA1c levels, BMI, and renal function were comparable between groups. Failure to achieve fusion occurred in 10.0% of SGLT2i users versus 18.7% of non-users (risk ratio 0.53, 95% CI 0.39–0.73, p<0.001). Kaplan–Meier analysis demonstrated significantly improved probability of maintained fusion among SGLT2i users (HR 0.53, 95% CI 0.38–0.75, p<0.001). The mean number of pseudarthrosis instances was also significantly lower among SGLT2i patients (0.40 vs 0.73, p=0.013). Postsurgical infection rates did not differ significantly (10.8% vs 8.3%, p=0.15), and survival analysis confirmed no increased hazard of infection with SGLT2i exposure (HR 1.35, 95% CI 0.92–1.99, p=0.21). Conclusion: In this multicenter analysis, SGLT2i use was associated with a significantly reduced risk of pseudarthrosis following hindfoot arthrodesis in patients with T2DM, without elevating infection risk. Beyond glycemic control, SGLT2i exert systemic effects—reducing insulin resistance, lowering advanced glycation end products, decreasing inflammation, and improving renal and cardiovascular function—that may create a more favorable biological environment for bone healing. The observed benefit is consistent with these mechanisms and highlights the importance of optimizing metabolic status in surgical patients. Future prospective studies should validate these findings and clarify the direct role of SGLT2i in promoting arthrodesis.
No takes yet. Share an insight, caveat, or question.
Mody et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: